Anonymous
Guest
Anonymous
Guest
I would exercise those options first thing Tuesday morning. This stock is headed for a crash.
I sold all my options as well. It might be easy to financially engineer earnings per share by cutting expenses i.e. employees but revenues will continue to fall as far as the eye can see. Most Merck drugs are in negative revenue mode- meaning continued fall in income going forward. Merck has only one option and that is to continue to cut employees to continue the fantasy.
Where did Merck go wrong? Merck fell from the best R&D pharma to the worst. Management wanted to pump their option price to make a boat load of money without regard to the company's future. Options to management can be detrimental to a company's future as has been demonstrated in Merck's case.
So what is Merck doing now? They are overpaying for a hep c drug that is entering a field of price commodity i.e. gilead and abbey. They overpaid 2 to 3 billion for a company with an antibiotic. It is a sad cycle Merck is in.